A5070627264- CRISPR and Genetic Engineering
- RNA and protein synthesis mechanisms
- CAR-T cell therapy research
- Advanced biosensing and bioanalysis techniques
- Robotic Path Planning Algorithms
- Robotics and Automated Systems
- Lysosomal Storage Disorders Research
- Innovative concrete reinforcement materials
- Glioma Diagnosis and Treatment
- Cancer Mechanisms and Therapy
- Pancreatic function and diabetes
- Robotic Mechanisms and Dynamics
- Glycosylation and Glycoproteins Research
- Innovations in Concrete and Construction Materials
- Modular Robots and Swarm Intelligence
- Immunotherapy and Immune Responses
The University of Melbourne
2023-2025
Peter MacCallum Cancer Centre
2023-2024
Walter and Eliza Hall Institute of Medical Research
2023
P.V. Narsimha Rao Telangana Veterinary University
2020
Abstract Aims/hypothesis Type 2 diabetes is a chronic metabolic disorder characterised by insulin resistance and sustained hyperglycaemia, major cause of blindness, kidney failure, heart attacks stroke. Our team has recently identified hexosaminidase A (HEXA) as an endocrine factor secreted the liver that regulates sphingolipid metabolism in skeletal muscle. Specifically, HEXA converts GM2 to GM3 gangliosides within cell-surface lipid rafts. Remodelling ganglioside composition enhances IGF1...
Synthetic biology has made it possible to rewire natural cellular responses treat disease, notably demonstrated by chimeric antigen receptor (CAR) T cells as cancer immunotherapy. Building on the success of T‐cell activation using synthetic receptors, field is now investigating how induction noncanonical signalling pathways and sophisticated gene circuitry can enhance antitumour phenotype engineered cells. This commentary explores two recently published studies that provide proof concept for...
ABSTRACT Single nucleotide variants (SNVs) are extremely prevalent in human cancers. For instance, KRAS mutations occur over 90% of pancreatic cancers and ∼40% colorectal Virtually all SNVs, most which remain clinically unactionable. The programmable RNA nuclease CRISPR-Cas13 has been deployed to specifically target RNAs such as overexpressed oncogenes fusion transcripts. However, silencing oncogenic SNVs with single-base precision remains challenging due the intrinsic mismatch tolerance...
Single-nucleotide variants (SNVs) are extremely prevalent in human cancers, although most of these remain clinically unactionable. The programmable RNA nuclease CRISPR-Cas13 has been deployed to specifically target oncogenic RNAs. However, silencing SNVs with single-base precision remains challenging due the intrinsic mismatch tolerance Cas13. Here, we show that introducing synthetic mismatches at precise positions spacer sequence enables de novo design guide RNAs [CRISPR (crRNAs)] strong...